Latest financials and China pharma exposure

Sinopharm Group Co Ltd maintains a strong position in China’s pharmaceutical sector with recent financials showing trailing twelve-month revenue of CNY 332.22 billion and earnings of HK$6.70 billion, according to Simply Wall St data. The company, listed on the Hong Kong Stock Exchange under ticker 1099, operates through production, distribution, retail, and other segments, serving domestic and international markets.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

Sinopharm Group Co Ltd: core business model

Sinopharm Group Co Ltd engages in the research, development, manufacture, distribution, and retail of pharmaceutical and healthcare products primarily in China. The company operates four key segments: Production, which includes chemical drugs, biological drugs, and traditional Chinese medicine; Distribution, handling wholesale of pharmaceuticals; Retail through pharmacy chains; and Others encompassing medical devices and equity investments. This integrated model positions it as China’s largest drug distributor by revenue.

The Production segment focuses on treatments for immunology, oncology, cardiovascular, and respiratory diseases, supporting domestic demand. Distribution leverages an extensive network covering over 90% of Chinese hospitals, ensuring supply chain efficiency. Recent trailing twelve-month revenue reached CNY 332.22 billion with a gross margin of 10.83%, per Simply Wall St as of 2026.

Main revenue and product drivers for Sinopharm Group Co Ltd

Distribution remains the primary revenue driver, accounting for the bulk of CNY 288.08 billion in reported revenue, driven by partnerships like those with global firms and state-backed initiatives in healthcare access. Production contributes through innovative drugs and generics, while Retail expands via over 10,000 outlets. Net profit margin stood at 2.02% on earnings per share of 1.57 CNY in the latest period.

Dividend yield of 2.8% appeals to income-focused investors, with a market cap of HK$65.84 billion underscoring scale. The company’s exposure to China’s aging population and policy-driven drug reimbursement boosts long-term drivers.

Industry trends and competitive position

China’s pharmaceutical market, valued at over USD 150 billion, grows at 8-10% annually, fueled by volume-based procurement and innovation policies. Sinopharm Group Co Ltd holds a leading 20%+ share in distribution, ahead of peers, benefiting from government ties as a state-owned enterprise. Its scale enables cost efficiencies amid US-China trade dynamics affecting supply chains.

Why Sinopharm Group Co Ltd matters for US investors

US investors gain exposure to China’s USD 1.5 trillion healthcare spend via Sinopharm’s Hong Kong listing, offering diversification from pure US plays. With ADRs and ETF inclusions like VanEck’s EMKT, it provides a hedge against domestic inflation through emerging market growth. HKEX trading in HKD facilitates access for international portfolios tracking Asia pharma.

Conclusion

Sinopharm Group Co Ltd stands as a cornerstone of China’s pharmaceutical ecosystem, with robust financials including CNY 332 billion in revenue and a strategic distribution network. Its position amid healthcare reforms and international partnerships offers visibility into Asia’s growth, though tied to policy and economic cycles in China. US investors monitor it for emerging market allocation potential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.